AZN—DANUBE phase-3 study in first-line bladder cancer fails both primary endpoints: i) Infinzi/tremelimumab (CTLA4) did not show statsig-better OS than chemotherapy alone in patients regardless of PD-L1 expression; and ii) Infinzi monotherapy did not show statsig-better OS than chemotherapy alone in patients with PD-L1>=25%.